SC 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

Loxo Oncology, Inc.

(Name of Issuer)

Common Stock, $.0001 par value

(Title of Class of Securities)

548862101

(CUSIP Number)

December 31, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of the section of the Act but shall be subject to all other provisions of that Act (however, see the Notes).

CUSIP No. 548862101

1	NAMES OF REPORTING PERSONS AI Loxo Holdings LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨        (b)  ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION State of Delaware
NUMBER OF SHARES BENEFICIALLY   OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   1,368,339
		6	SHARED VOTING POWER   0
		7	SOLE DISPOSITIVE POWER   1,368,339
		8	SHARED DISPOSITIVE POWER   0
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,368,339
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.23%1
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO (Limited Liability Company)

¹  Based on 16,634,063 outstanding shares of common stock as of November 11, 2014 as reported on the Issuer’s Form 10-Q for the period ended September 30, 2014 filed with the Securities and Exchange Commission on November 14, 2014.

2 of 11

CUSIP No. 548862101

1	NAMES OF REPORTING PERSONS AI Value Holdings LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨        (b)  ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION State of Delaware
NUMBER OF SHARES BENEFICIALLY   OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   0
		6	SHARED VOTING POWER   1,368,339
		7	SOLE DISPOSITIVE POWER   0
		8	SHARED DISPOSITIVE POWER   1,368,339
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,368,339
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.23%1
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO (Limited Liability Company)

¹  Based on 16,634,063 outstanding shares of common stock as of November 11, 2014 as reported on the Issuer’s Form 10-Q for the period ended September 30, 2014 filed with the Securities and Exchange Commission on November 14, 2014.

3 of 11

CUSIP No. 548862101

1	NAMES OF REPORTING PERSONS Access Industries Management, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨        (b)  ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION State of Delaware
NUMBER OF SHARES BENEFICIALLY   OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   0
		6	SHARED VOTING POWER   1,368,339
		7	SOLE DISPOSITIVE POWER   0
		8	SHARED DISPOSITIVE POWER   1,368,339
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,368,339
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.23%1
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO (Limited Liability Company)

¹  Based on 16,634,063 outstanding shares of common stock as of November 11, 2014 as reported on the Issuer’s Form 10-Q for the period ended September 30, 2014 filed with the Securities and Exchange Commission on November 14, 2014.

4 of 11

CUSIP No. 548862101

1	NAMES OF REPORTING PERSONS Len Blavatnik
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a)  ¨        (b)  ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION United States of America
NUMBER OF SHARES BENEFICIALLY   OWNED BY EACH REPORTING PERSON WITH		5	SOLE VOTING POWER   0
		6	SHARED VOTING POWER   1,368,339
		7	SOLE DISPOSITIVE POWER   0
		8	SHARED DISPOSITIVE POWER   1,368,339
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,368,339
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.23%1
12	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN

¹  Based on 16,634,063 outstanding shares of common stock as of November 11, 2014 as reported on the Issuer’s Form 10-Q for the period ended September 30, 2014 filed with the Securities and Exchange Commission on November 14, 2014.

5 of 11

CUSIP No. 548862101

Item 1.

(a) Name of Issuer:

Loxo Oncology, Inc. (the “Issuer”)

(b) Address of Issuer’s Principal Executive Offices:

One Landmark Square, Suite 1122

Stamford, CT 06901

Item 2.

(a) Name of Person Filing:

This filing is being made on behalf of:

AI Loxo Holdings LLC

AI Value Holdings LLC

Access Industries Management, LLC

Len Blavatnik

(b) Address of Principal Business Office or, if none, Residence

AI Loxo Holdings LLC

c/o Access Industries, Inc.

730 Fifth Avenue, 20^th Floor

New York, NY 10019

AI Value Holdings LLC

c/o Access Industries, Inc.

730 Fifth Avenue, 20^th Floor

New York, NY 10019

Access Industries Management, LLC

c/o Access Industries, Inc.

730 Fifth Avenue, 20^th Floor

New York, NY 10019

Len Blavatnik

c/o Access Industries, Inc.

730 Fifth Avenue, 20^th Floor

New York, NY 10019

(c) Citizenship:

AI Loxo Holdings LLC is a limited liability company organized under the laws of the State of Delaware.

AI Value Holdings LLC is a limited liability company organized under the laws of the State of Delaware.

6 of 11

Access Industries Management, LLC is a limited liability company organized under the laws of the State of Delaware.

Mr. Blavatnik is a citizen of the United States of America.

(d) Title of Class of Securities:

Common Stock

(e) CUSIP Number:

548862101

Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(a)    ¨    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)    ¨    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)    ¨    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)    ¨    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)    ¨    An investment adviser in accordance with §240.13d-1(b) (1)(ii)(E);

(f)    ¨    An employee benefit plan or endowment fund in accordance with §240.13d-1(b) (1)(ii)(F);

(g)    ¨    A parent holding company or control person in accordance with §240.13d-1(b) (1)(ii)(G);

(h)    ¨    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)    ¨    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)    ¨    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

Not Applicable.

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

See the responses to Item 9 on the attached cover pages.

7 of 11

1,368,339 shares of the Issuer’s Class A Common Stock are owned directly by AI Loxo Holdings LLC (“AI Loxo”). Each of AI Value Holdings, LLC (“AI Value”), Access Industries Management, LLC (“AIM LLC”) and Len Blavatnik may be deemed to beneficially own the shares of common stock held directly by AI Loxo. AI Value is the sole member of AI Loxo and, as a result, may be deemed to share voting and investment power over the shares of common stock beneficially owned by AI Loxo. AIM LLC controls AI Value and, as a result, may be deemed to share voting and investment power over the shares beneficially owned by AI Loxo. Len Blavatnik controls AIM LLC and, as a result, may be deemed to share voting and investment power over the shares of common stock beneficially owned by AI Loxo. Each of AI Value, AIM LLC and Len Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, other than AI Loxo, disclaims beneficial ownership of the shares held by AI Loxo.

(b) Percent of class:

8.23%*

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

AI Loxo has sole power to vote or direct the vote of 1,368,339 shares.

(ii) Shared power to vote or to direct the vote:

AI Value, AIM LLC and Len Blavatnik may be deemed to have shared power to vote or direct the vote of 1,368,339 shares. Each of AI Value, AIM LLC and Mr. Blavatnik disclaims such beneficial ownership of such shares.

(iii) Sole power to dispose or to direct the disposition:

AI Loxo has sole power to dispose or direct the disposition of 1,368,339 shares.

(iv) Shared power to dispose or to direct the disposition:

AI Value, AIM LLC and Len Blavatnik may be deemed to have shared power to dispose or direct the disposition of 1,368,339 shares. Each of AI Value, AIM LLC and Mr. Blavatnik disclaims such beneficial ownership of such shares.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ¨:

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

* Based on 16,634,063 outstanding shares of common stock as of November 11, 2014 as reported on the Issuer’s Form 10-Q for the period ended September 30, 2014 filed with the Securities and Exchange Commission on November 14, 2014.

8 of 11

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certification.

Not applicable.

9 of 11

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 12, 2015

AI LOXO HOLDINGS LLC	By:	Access Industries Management, LLC, its Manager
	/s/ Alejandro Moreno
	Signature
	Alejandro Moreno / Executive Vice President
	Name/Title
AI VALUE HOLDINGS, LLC	By:	Access Industries Management, LLC, its Manager
	/s/ Alejandro Moreno
	Signature
	Alejandro Moreno / Executive Vice President
	Name/Title
ACCESS INDUSTRIES MANAGEMENT, LLC	/s/ Alejandro Moreno
	Signature
	Alejandro Moreno / Executive Vice President
	Name/Title
	*
	Signature
	Len Blavatnik
	Name

* The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

By:	/s/ Alejandro Moreno
Name:	Alejandro Moreno
	Attorney-in-Fact

10 of 11

EX-99.1

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13G dated February 12, 2015 relating to the Common Stock, par value $0.0001 of Loxo Oncology, Inc. shall be filed on behalf of the undersigned.

AI LOXO HOLDINGS LLC	By:	Access Industries Management, LLC, its Manager
	/s/ Alejandro Moreno
	Signature
	Alejandro Moreno / Executive Vice President
	Name/Title
AI VALUE HOLDINGS, LLC	By:	Access Industries Management, LLC, its Manager
	/s/ Alejandro Moreno
	Signature
	Alejandro Moreno / Executive Vice President
	Name/Title
ACCESS INDUSTRIES MANAGEMENT, LLC	/s/ Alejandro Moreno
	Signature
	Alejandro Moreno / Executive Vice President
	Name/Title
	*
	Signature
	Len Blavatnik
	Name

* The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

By:	/s/ Alejandro Moreno
Name:	Alejandro Moreno
	Attorney-in-

EX-99.2

Exhibit 99.2

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints Lincoln Benet, Alejandro Moreno and Richard Storey, and each of them individually, the undersigned’s true and lawful attorney-in-fact to:

• execute for and on behalf of the undersigned, in the undersigned’s capacity as a beneficial owner of Loxo Oncology, Inc. (the “Company”), (i) Forms 3, 4 and 5 and any other forms required to be filed in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and the rules thereunder (a “Section 16 Form”), (ii) all forms and schedules in accordance with Section 13(d) of the Exchange Act and the rules thereunder, including all amendments thereto (a “Section 13 Schedule”), (iii) a Form ID Application, Passphrase Update Application and/or request to convert from paper only to electronic filer with the US Securities and Exchange Commission and to obtain access codes to file on EDGAR and any other forms required to be filed or submitted in accordance with Regulation S-T promulgated by the United States Securities and Exchange Commission (or any successor provision) in order to file a Section 13 Schedule or a Section 16 Form electronically (a “Form ID”, and, together with a Section 13 Schedule and Section 16 Form, the “Forms and Schedules”) and (iv) any Joint Filing Agreement or similar agreement with respect to the filing of any of the Forms or Schedules in (i) through (iii) above;

• do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Forms and Schedules, complete and execute any amendment or amendments thereto, and timely file such Forms and Schedules with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

• take any other action of any type whatsoever in connection with the foregoing which, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as he may approve in his discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each such attorney-in- fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this

Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that each such attorney-in-fact is serving in such capacity at the request of the undersigned, and is not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 13 or Section 16 of the Exchange Act.

The Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any Forms and Schedules with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

From and after the date hereof, any Power of Attorney previously granted by the undersigned concerning the subject matter hereof is hereby revoked.

IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney on this 9^th day of July, 2014.

LEONARD BLAVATNIK

/s/ Leonard Blavatnik

2